Pharma Rep Focus

Axsome bounces back as FDA clears depression drug

pharmaphorum

AUGUST 21, 2022

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Auvelity isn’t the first NMDA-targeting antidepressant to reach the market.

FDA

FDA Marketing Pharma Sales

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Sales

Sales Patients Competition Marketing

Axsome bounces back as FDA clears depression drug

J&J builds case for antidepressant Spravato with head-to-head trial

Stay Connected